A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and > 2% blood eosinophils

Respiratory Medicine

Volumn 109, Issue 7, 2015, Pages 860-869

  Marks Konczalik, Joanna ^a   Costa, Maria ^a   Robertson, Jon ^a   McKie, Elizabeth ^a   Yang, Shuying ^a   Pascoe, Steven ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

COPD; Eosinophils; Exacerbations; Losmapimod; p38 MAPK inhibitor

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; FIBRINOGEN; LOSMAPIMOD; PLACEBO; 6-(5-((CYCLOPROPYLAMINO)CARBONYL)-3-FLUORO-2-METHYLPHENYL)-N-(2,2-DIMETHYLPRPYL)-3-PYRIDINECARBOXAMIDE; CYCLOPROPANE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DEPENDENCE TREATMENT; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL COUNT; FEMALE; FIBRINOGEN BLOOD LEVEL; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); PHENOTYPE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEADY STATE; TREATMENT DURATION; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EOSINOPHIL; FOLLOW UP; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84930754960     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2015.05.003     Document Type: Article

References (23)

1. The global initiative for chronic obstructive lung disease (GOLD) revised 2014; www.goldcopd.com. Last accessed 10 October 2014.
2. A.G. Agusti COPD, a multicomponent disease: implications for management Respir Med 99 2005 670 682
3. M.K. Han, A. Agusti, P.M. Calverley, B.R. Celli, G. Criner, J.L. Curtis, L.M. Fabbri, J.G. Goldin, P.W. Jones, W. MacNee, B.J. Make, K.F. Rabe, S.I. Rennard, F.C. Sciurba, E.K. Silverman, J. Vestbo, G.R. Washko, E.F.M. Wouters, and F.J. Martinez Chronic obstructive pulmonary disease phenotypes. The future of COPD Am J Respir Crit Care Med 182 2010 598 604
4. J.R. Hurst, J. Vestbo, A. Anzuet, N. Locantore, H. Müllerova, R. Tal-Singer, B. Miller, D.A. Lomas, A. Agusti, W. MacNee, P. Calverley, S. Rennard, E.F.M. Wouters, J.A. Wedzicha for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 363 2010 1128 1138
5. S.I. Rennard, P.M.A. Calverley, U.M. Goehring, D. Bredenbroker, and F.J. Martinez Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD Respir Res 12 2011 18
6. A. Agusti, P.M.A. Calverley, B. Celli, H.O. Coxson, L.D. Edwards, D.A. Lomas, W. MacNee, B.E. Miller, S. Rennard, E.K. Silverman, R. Tal-Singer, E. Wouters, J.C. Yates, J. Vestbo for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators Characterisation of COPD heterogeneity in the ECLIPSE cohort Respir Res 11 2010 122
7. M. Bafadhel, S. McKenna, S. Terry, V. Mistry, C. Reid, P. Haldar, M. McCormick, K. Haldar, T. Kebadze, and A. Duvoix Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers Am J Respir Crit Care Med 184 2011 662 671
8. C.E. Brightling, S. McKenna, and B. Hargadon Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease Thorax 60 3 2005 193 198
9. S. Saha, and C.E. Brightling Eosinophilic airway inflammation in COPD Int J Chron Obstruct Pulmon Dis 1 2006 39 47
10. M. Bafadhel, S. McKenna, S. Terry, V. Mistry, M. Pancholi, P. Venge, D.A. Lomas, M.R. Barer, S.L. Johnston, and I.D. Pavord Blood eosinophils to direct corticosteroid treatment of exacerbations of COPD: a randomized placebo controlled trial Am J Respir Crit Care Med 186 2012 48 55
11. E. Pizzichini, M.M. Pizzichini, P. Gibson, K. Parameswaran, G.J. Gleich, L. Berman, J. Dolovich, and F.E. Hargreave Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis Am J Respir Crit Care Med 158 1998 1511 1517
12. C.E. Brightling, W. Monteiro, R. Ward, D. Parker, M.D. Morgan, A.J. Wardlaw, and I.D. Pavord Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial Lancet 356 2000 1480 1485
13. S.D. Aaron, K.L. Vandemheen, F. Maltais, S.K. Field, D. Sin, J. Bourbeau, D.D. Marciniuk, M.J. FitzGerald, P. Nair, and R. Mallick TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial Thorax 68 2013 142 148
14. K.F. Chung p38 mitogen-activated protein kinase pathways in asthma and COPD Chest 139 2011 1470 1479
15. M. Elkhawad, J.H.F. Rudd, and L. Sarov-Blat Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis JACC Cardiovasc Imaging 5 2012 911 922
16. E.D. Martin, G.F. De Nicola, and M.S. Marber New therapeutic targets in cardiology p38 alpha mitogen-activated protein kinase for ischemic heart disease Circulation 126 2012 357 368
17. M.S. Marber, B. Rose, and Y. Wang The p38 mitogen-activated protein kinase pathway.A potential target for intervention in infarction, hypertrophy, and heart failure J Mol Cell Cardiol 51 2011 485 490
18. H. Watz, H. Barnacle, B.F. Hartley, and R. Chan Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial Lancet Respir Med 2 1 2014 Jan 63 72
19. N. Khorasani, J. Baker, M. Johnson, K.F. Chung, and P. Bhavsar Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD Int J COPD 10 2015 1 9
20. P. Bhavsar, N. Khorasani, M. Hew, M. Johnson, and K.F. Chung Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma Eur Respir J 35 2010 750 756
21. J.S.C. Arthur, and S.C. Ley Mitogen-activated protein kinases in innate immunity Nat Rev Immunol 13 2013 679 692
22. M.C. Genovese Inhibition of p38: has the fat lady sung? Arthritis Rheum 60 2009 317 320
23. S. Pascoe, N. Locantore, M.T. Dransfi eld, N.C. Barnes, and I.D. Pavord Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials Lancet Respir Med 2015 10.1016/S2213-2600(15)00106-X published online April 13